The European Commission has decided to approve the drug Vyepti (eptinezumab) for the preventive treatment of migraines in adults who have at least four migraine attacks per month.
The announcement was expected, as the European Medicines Agency’s Expert Committee on Medicinal Products for Human Use, CHMP, issued a favourable statement in November l...
Lundbeck behind the first EU-approved intravenous migraine treatment
A preventive, intravenous treatment for migraines has been approved in the EU for the first time.
Få tillgång till hela artikeln - enkelt och snabbt
Provprenumeration
Skapa en provprenumeration
Prova nu
Prenumeration
Välj mellan våra prenumerationer på Life Science Sweden och hitta vad som passar dig och/eller ditt företag
Se prenumerationer
